 |
|
University of Leicester research reveals rice bran could reduce risk of intestinal cancer
March 27, 2007Report in British Journal of Cancer provides preclinical evidence on possible health benefits of rice bran
A study by biomedical scientists at the University of Leicester has revealed for the first time that rice bran could reduce the risk of intestinal cancer.
The research in the University's Department of Cancer Studies and Molecular Medicine has not been tested on humans, but research in the laboratory has produced promising results.
The research has been published in the British Journal of Cancer.
The results of a controlled laboratory study in a preclinical model of gastrointestinal adenoma demonstrated that consumption of a high daily dose of stabilized rice bran caused an average 51% reduction in the number of precancerous adenomas in the intestinal tract.
Professor Andreas Gescher of the University of Leicester in the UK, the principal investigator, said:
"We compared the cancer-preventive efficacy of rice bran with respect to prostate, breast and intestinal cancers. Whilst there was no effect of rice bran on the development of prostate or breast cancer, rice bran significantly retarded the development of intestinal adenomas. The effect was dependent on the fibre content of the bran. The dose we used translates into approximately 200g rice bran per day in humans. We believe a promising area of future research would be to study the potential colorectal cancer-preventing properties of stabilized rice bran.
"It is known that bran from wheat and rye have anti-cancer properties but this is the first time that this has been shown for rice bran. It appears that rice bran may have a role to play in reducing the development of adenomas, which can be a pre-cursor to cancer. No one has compared the efficacy of the different brans, such as rice, wheat, rye or oat and this may be an interesting future direction for researchers.\\\
University of Leicester
The research has been published in the British Journal of Cancer.
The results of a controlled laboratory study in a preclinical model of gastrointestinal adenoma demonstrated that consumption of a high daily dose of stabilized rice bran caused an average 51% reduction in the number of precancerous adenomas in the intestinal tract.
Professor Andreas Gescher of the University of Leicester in the UK, the principal investigator, said:
"We compared the cancer-preventive efficacy of rice bran with respect to prostate, breast and intestinal cancers. Whilst there was no effect of rice bran on the development of prostate or breast cancer, rice bran significantly retarded the development of intestinal adenomas. The effect was dependent on the fibre content of the bran. The dose we used translates into approximately 200g rice bran per day in humans. We believe a promising area of future research would be to study the potential colorectal cancer-preventing properties of stabilized rice bran.
"It is known that bran from wheat and rye have anti-cancer properties but this is the first time that this has been shown for rice bran. It appears that rice bran may have a role to play in reducing the development of adenomas, which can be a pre-cursor to cancer. No one has compared the efficacy of the different brans, such as rice, wheat, rye or oat and this may be an interesting future direction for researchers.\\\
University of Leicester
Intestinal Cancer Current Events and Intestinal Cancer News RSSColon cancer a disease of hormone deficiency, Jefferson team finds
Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia have found new evidence suggesting that colon cancer is actually a disease of missing hormones that could potentially be treated by hormone replacement therapy.
Like a snail through the intestinal canal
The medical device currently used for intestinal research, the colonsope, causes patients great discomfort. At TU Delft, an alternative method has been developed, inspired by the way in which snails move.
OHSU study says stem cell 'fusion' occurs in tumors
An Oregon Health & Science University study is adding credence to an increasingly popular theory that fusion is what bonds stem cells with bone marrow cells to regenerate organ tissue.
New point system enhances prognosis for GIST patients
A research team at the Sahlgrenska Academy at Göteborg University in Sweden has developed a point system for calculating risk that will help physicians determine prognoses, survival rates, and the best methods of treatment for patients suffering from GIST tumors. The findings are being published in the prestigious medical journal Cancer. GIST is a soft tissue tumor that occurs in the abdomen but differs from gastro-intestinal cancer. Nearly two hundred Swedes are affected every year. Long-term survival rates have been low. GIST tumors can grow very large and occupy a major section of the abdomen. Some tumors weigh as much as five kilos. For many years the only method of treatment was surg
No Benefits From Vitamin Supplements In Protection Against Gastro-Intestinal Cancer (pp 1193, 1219)
A systematic review and meta-analysis (pooled analysis) of previously published randomised trials in this week's issue of THE LANCET provides strong evidence that antioxidant supplements (such as vitamin supplements) are not effective in protecting against gastro-intestinal cancer. Some combinations of supplements may slightly increase gastro-intestinal cancer risk, whereas selenium may be associated with a risk reduction.
When Cancer Runs in the Family
Almost all tumor types have a genetically based form Most cancers occur sporadically. At least 5.5 percent of cancer cases are based on a genetic predisposition. These are usually identified because first-degree relatives develop the same type of tumor. So far, scientists have presumed that only a few types of tumor have such a familial form. However, Professor Kari Hemminki of the Division of Molecular-Genetic Epidemiology of the Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ), has now found familial forms of almost all tumor types. In the families affected, both the offspring and siblings of a cancer sufferer are at an increased risk to develop the same disorder. Sw
Promising new methods of treatment for fatal abdominal tumor
GIST is a soft-parts tumor that occurs in the abdomen but is distinguishable from gastro-intestinal cancer. Previously, surgery has been the only treatment option since this type of tumor does not respond to either chemotherapy or radiation. Scientists at the Sahlgrenska Academy at Göteborg University have now shown that the prognosis for GIST patients improves considerably if surgery is combined with a new medicinal treatment.
More Intestinal Cancer Current Events and Intestinal Cancer News Articles
| © 2008 BrightSurf.com |